Bfactory completes Nordic coverage with latest launch of Vetramil skin and wound care portfolio
Bfactory International has secured a partnership with Icevet for distribution of its Vetramil medical-grade honey wound and skincare product line in Iceland.
This latest deal means the Vetramil product line is now available in all of the Nordic countries – Denmark, Finland, Iceland, Norway and Sweden.
The company, which is the business development subsidiary of the Netherlands based R&D-focused parent company Bfactory Health Products, is currently expanding the coverage of its lead product line globally.
"While Iceland may not be the biggest market, we consider this as an important milestone as Nordic countries are the definite forerunners in a fight against antibiotic resistance and therefore having Vetramil available throughout this region has been an important strategic goal for us," Bfactory International co-founder Dr Willem Bosma told Animal Pharm.
After successfully covering the Nordic region, the company is now focusing on UK as the last from the big five EU markets. In the longer-term, Bfactory International has its sight set on the US market.
"Honey-based products are being recognized and veterinarians are realizing their effectiveness," said Dr Bosma. "Thus, we see that the momentum is right to start expanding our markets outside Europe."
According to Bfactory their approved human medical device products have honey-based efficacy for various skin problems and wound treatments, both in chronic and infected wounds. The company said its Vetramil products have been especially developed for optimal care of animals.
All Vetramil products are based on special honey and essential oils, which are selected for their skin caring and purifying properties. Vetramil portfolio is developed by Bfactory in close collaboration with the Wageningen University in the Netherlands and aimed for ease-of-use by veterinarians and pet owners.